A Case Study of Psoriasis Vulgaris After COVID-19 Vaccination in Saudi Arabia

Authors

  • Hassan Alwafi Pharmacology and Toxicology Department, Faculty of Medicine, Umm Al Qura University, Makkah
  • Nedaa Alsulaimani Department of Medicine and Surgery, Faculty of Medicine, Umm Al-Qura University, Makkah
  • Mohammed E. Almalki Department of Medicine and Surgery, Faculty of Medicine, Umm Al-Qura University, Makkah
  • Asma Mohammad Banjar Faculty of Pharmacy, Umm Al Qura University, Makkah
  • Reham Abdullah Alamri Department of Clinical Nutrition, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah
  • Danya Alwafi Department of Dermatology, Al-Noor Specialist Hospital, Ministry of Health, Makkah
  • Anan S. Jarab - College of Pharmacy, Al Ain University, Abu Dhabi P.O. Box 112612, United Arab Emirates - AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi P.O. Box 112612, United Arab Emirates - Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan
  • Asaleh El-Qasem Faculty of Pharmacy, University of Jordan, Amman, Jordan
  • Yosra J. Alhartani Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amman
  • Abdallah Y Naser Department of Applied Pharmaceutical Sciences and Clinical Pharmacy, Faculty of Pharmacy, Isra University, Amma https://orcid.org/0000-0001-8440-7446 (unauthenticated)

DOI:

https://doi.org/10.15395/mkb.v57.3855

Keywords:

Drug-related side effects and adverse reactions, COVID-19, SARS-CoV-2, vaccines, vulgaris

Abstract

Since the COVID-19 vaccines have been approved, worldwide reports of adverse events have been reported. Although a few cases of Psoriasis vulgaris have been reported after COVID-10 vaccination, there is currently limited evidence to establish a direct relationship between the vaccine and this condition. A 27-year-old Saudi woman, previously healthy and had no medical issues, reported skin lesions on her lower legs, which she noticed ten (10) days after receiving the first dose of the Pfizer COVID-19 vaccine. The patient had no prior history of such lesions or any family history of psoriasis. Joint pain was not observed. A diagnosis of psoriasis vulgaris was made, and the patient was treated with Daivobet® cream, urea cream 10%, and full-body NB-UVB light therapy three times a week for up to two months. The patient's condition improved partially. This report presents the first known case of psoriasis vulgaris after the COVID-19 vaccine in the Middle East. Further research is needed to fully understand this connection. The study emphasizes the significance of a thorough medical history and evaluation for precise diagnosis and treatment.

Downloads

Published

2025-03-31

Issue

Vol. 57 No. 1 (2025)

Section

Case Report

License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Under this license, authors retain copyright and grant Majalah Kedokteran Bandung the right of first publication. Others may share, remix, and adapt the work for non-commercial purposes, provided that appropriate credit is given to the author and to Majalah Kedokteran Bandung as the initial place of publication.

For details, please see: https://creativecommons.org/licenses/by-nc/4.0/

 

How to Cite

A Case Study of Psoriasis Vulgaris After COVID-19 Vaccination in Saudi Arabia. (2025). Majalah Kedokteran Bandung, 57(1), 81-86. https://doi.org/10.15395/mkb.v57.3855